App-Quantinova.ai

Neoadjuvant enzalutamide (ENZA) and abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus AA+ LHRHa in localized high-risk prostate cancer (LHRPC).

Eleni Efstathiou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)A University of Chicago phase II consortium trial.

Maha Hussain - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

CB-7598

AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.

Emmanuel S. Antonarakis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Fine tuning metabolism of biochemically active abiraterone metabolites to optimize anti-androgen therapy in prostate cancer.

Nima Sharifi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

Johann S. De Bono - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

PSA response in black and white patients treated with abiraterone acetate (AA) for metastatic castrate resistant prostate cancer (mCRPC).

Sundhar Ramalingam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-naive metastatic castration-resistant prostate cancer (mCRPC).

Alexander William Wyatt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P).

Manish Kohli - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

David Wise - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.

Ignacio Duran - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Sunil Parimi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer.

Charles J. Ryan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Galeterone in treatment-naive patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.

Mary-Ellen Taplin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Re-treatment with radium-223: An international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases.

A. Oliver Sartor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).

Niven Mehra - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).

Eric Jay Small - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

CB-7598

Assessment of central nervous system (CNS) and dose reduction events in patients treated with abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ).

Dominic Pilon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

CB-7598

ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.

Niranjan Sathyanarayana Rao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.

Nicholas J. Vogelzang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Retrospective analysis of prognostic factors for survival in metastatic castration-resistant prostate cancer patients (mCRPC) treated with abiraterone.

Krisztina Biro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Filters

959 Abstracts